A Phase II Study Of Epothilone Analog BMS-247550 In Patients With Metastatic Gastric Adenocarcinoma Previously Treated With A Fluoropyrimidine And/Or Platinum
OBJECTIVES: I. Determine the clinical activity of BMS-247550 in terms of response rate in
patients with recurrent metastatic gastric cancer previously treated with a fluoropyrimidine
or platinum regimen. II. Determine the safety of this drug in this patient population. III.
Determine the duration of response, time to progression, and survival of patients treated
with this drug.
OUTLINE: This is a multicenter study. Patients receive BMS-247550 IV over 1 hour on day 1.
Treatment repeats every 21 days for up to 18 courses in the absence of disease progression
or unacceptable toxicity. Patients achieving a complete response (CR) receive up to 4
additional courses after CR. Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 21-58 patients will be accrued for this study within 12
Primary Purpose: Treatment
Manish A. Shah, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|